A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting

Trial Profile

A Safety and Tolerability Study of Levalbuterol Tartrate HFA Inhalation Aerosol Metered Dose Inhaler (MDI) in Pediatric Subjects Birth to ≤ 48 Months of Age With Reactive Airways Disease in an Acute Setting

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Apr 2016

At a glance

  • Drugs Levosalbutamol (Primary)
  • Indications Bronchospasm
  • Focus Adverse reactions; Registrational
  • Sponsors Sunovion Pharmaceuticals
  • Most Recent Events

    • 14 Apr 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov
    • 24 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
    • 12 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top